PAVmed Sales General And Administrative To Revenue from 2010 to 2025

PAVMZ Stock  USD 0  0  30.00%   
PAVmed Series Sales General And Administrative To Revenue yearly trend continues to be fairly stable with very little volatility. Sales General And Administrative To Revenue will likely drop to 13.79 in 2025. During the period from 2010 to 2025, PAVmed Series Sales General And Administrative To Revenue regression line of annual values had r-squared of  0.09 and arithmetic mean of  47.71. View All Fundamentals
 
Sales General And Administrative To Revenue  
First Reported
2010-12-31
Previous Quarter
14.51
Current Value
13.79
Quarterly Volatility
22.1572141
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check PAVmed Series financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PAVmed Series' main balance sheet or income statement drivers, such as Interest Expense of 1.2 M, Selling General Administrative of 37.4 M or Other Operating Expenses of 86 M, as well as many indicators such as Price To Sales Ratio of 13.27, Dividend Yield of 3.0E-4 or Days Sales Outstanding of 14.05. PAVmed financial statements analysis is a perfect complement when working with PAVmed Series Valuation or Volatility modules.
  
Check out the analysis of PAVmed Series Correlation against competitors.

Latest PAVmed Series' Sales General And Administrative To Revenue Growth Pattern

Below is the plot of the Sales General And Administrative To Revenue of PAVmed Series Z over the last few years. It is PAVmed Series' Sales General And Administrative To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PAVmed Series' overall financial position and show how it may be relating to other accounts over time.
Sales General And Administrative To Revenue10 Years Trend
Slightly volatile
   Sales General And Administrative To Revenue   
       Timeline  

PAVmed Sales General And Administrative To Revenue Regression Statistics

Arithmetic Mean47.71
Geometric Mean41.83
Coefficient Of Variation46.44
Mean Deviation12.78
Median51.13
Standard Deviation22.16
Sample Variance490.94
Range96.2409
R-Value(0.30)
Mean Square Error479.58
R-Squared0.09
Significance0.26
Slope(1.38)
Total Sum of Squares7,364

PAVmed Sales General And Administrative To Revenue History

2025 13.79
2024 14.51
2023 12.62
2022 108.86

About PAVmed Series Financial Statements

PAVmed Series investors use historical fundamental indicators, such as PAVmed Series' Sales General And Administrative To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in PAVmed Series. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Sales General And Administrative To Revenue 14.51  13.79 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.